Welcome to our dedicated page for TELYRX HOLDINGS news (Ticker: TELYF), a resource for investors and traders seeking the latest updates and insights on TELYRX HOLDINGS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TELYRX HOLDINGS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TELYRX HOLDINGS's position in the market.
TelyRx (TSX: TELY, OTCQX: TELYF) will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 8:30 a.m. ET. The company expects to release the results by news release at approximately 7:00 a.m. ET the same day.
Investors can join via telephone using the provided North American and international dial-in numbers or access a live webcast through the specified online link, with participants asked to connect about 15 minutes early.
TelyRx (TSX: TELY, OTCQX: TELYF) announced a major expansion of its Clearwater, Florida headquarters and pharmacy operations after surpassing one million prescriptions filled and reporting first-quarter revenue growth of 180% year-over-year. The move more than triples the company’s physical footprint to support rising demand for its digital healthcare and online pharmacy platform.
TelyRx’s integrated platform links patients with licensed providers and pharmacy services for FDA-approved medications used in routine care. The company is also recruiting across pharmacy, clinical and fulfillment roles to preserve service levels and support scaling as adoption of virtual care solutions increases.
TelyRx Holdings (TSX: TELY, OTCQX: TELYF) announced that its subordinate voting shares are now DTC eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company. According to TelyRx, this is expected to simplify trading, improve settlement efficiency, and enhance liquidity and accessibility for U.S. investors by enabling trading across a wider network of brokerage firms.
TelyRx (OTCQX:TELYF) reported voting results from its June 15, 2026 Annual Meeting of Shareholders. All nominated directors were elected and the additional resolution submitted to shareholders was approved.
Votes for nominees ranged from 8,788,172 (69.42%) for Michael Handler to 12,659,534 (100%) for Andrew Brandt.
TelyRx (OTCQX:TELYF) announced it has surpassed 1 million prescriptions filled nationwide since inception, marking a key growth milestone for its digital, cash-pay pharmacy platform.
The company offers 450+ FDA-approved medications for 60+ conditions and says its infrastructure can serve over 97% of the U.S. population.
TelyRx (TSX:TELY, OTCQX:TELYF), a technology-enabled healthcare and pharmacy services company, announced its subordinate voting shares now trade on the OTCQX Best Market in the United States under symbol TELYF.
The shares will continue trading on the TSX. According to TelyRx, OTCQX trading offers U.S. investors easier access in U.S. dollars and supports goals of improved market accessibility, liquidity, and long-term shareholder value.